Ann Vanderplas

2.8k total citations · 2 hit papers
24 papers, 1.9k citations indexed

About

Ann Vanderplas is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ann Vanderplas has authored 24 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pathology and Forensic Medicine, 10 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ann Vanderplas's work include Lymphoma Diagnosis and Treatment (14 papers), Viral-associated cancers and disorders (9 papers) and CNS Lymphoma Diagnosis and Treatment (4 papers). Ann Vanderplas is often cited by papers focused on Lymphoma Diagnosis and Treatment (14 papers), Viral-associated cancers and disorders (9 papers) and CNS Lymphoma Diagnosis and Treatment (4 papers). Ann Vanderplas collaborates with scholars based in United States, Germany and Canada. Ann Vanderplas's co-authors include Joyce C. Niland, Eunice Chang, Myron S. Czuczman, Douglas W. Blayney, Maria Alma Rodriguez, Michael Millenson, Andrew D. Zelenetz, Ann S. LaCasce, Gregory A. Abel and Leo I. Gordon and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Diabetes Care.

In The Last Decade

Ann Vanderplas

24 papers receiving 1.9k citations

Hit Papers

An enhanced International Prognostic Index (NCCN-IPI) for... 2012 2026 2016 2021 2013 2012 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
    2013 609 citations Zheng Zhou, Laurie H. Sehn et al. Blood profile →
  2. Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network
    2012 475 citations Nancy U. Lin, Ann Vanderplas et al. Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ann Vanderplas United States 15 943 819 347 342 300 24 1.9k
Aart Beeker Netherlands 18 211 0.2× 452 0.6× 36 0.1× 174 0.5× 228 0.8× 56 1.1k
Pascal Wolter Belgium 26 152 0.2× 1000 1.2× 89 0.3× 58 0.2× 308 1.0× 86 2.0k
Stephen J. Noga United States 24 208 0.2× 1.1k 1.3× 93 0.3× 109 0.3× 57 0.2× 82 2.4k
Daniel T. Ruan United States 29 263 0.3× 764 0.9× 985 2.8× 75 0.2× 245 0.8× 62 3.1k
Antonella Brunello Italy 23 138 0.1× 907 1.1× 67 0.2× 58 0.2× 252 0.8× 119 1.8k
Janine Nuver Netherlands 21 188 0.2× 452 0.6× 126 0.4× 136 0.4× 119 0.4× 70 1.8k
Uma Kher United States 18 520 0.6× 898 1.1× 196 0.6× 424 1.2× 89 0.3× 36 2.1k
Jennifer Kim United States 22 46 0.0× 326 0.4× 329 0.9× 147 0.4× 174 0.6× 88 1.9k
Azeez Farooki United States 24 233 0.2× 1.5k 1.8× 224 0.6× 48 0.1× 118 0.4× 61 2.7k
J Rovenský Slovakia 15 236 0.3× 222 0.3× 134 0.4× 149 0.4× 42 0.1× 47 2.2k

Countries citing papers authored by Ann Vanderplas

Since Specialization
Citations

This map shows the geographic impact of Ann Vanderplas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann Vanderplas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann Vanderplas more than expected).

Fields of papers citing papers by Ann Vanderplas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann Vanderplas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann Vanderplas. The network helps show where Ann Vanderplas may publish in the future.

Co-authorship network of co-authors of Ann Vanderplas

This figure shows the co-authorship network connecting the top 25 collaborators of Ann Vanderplas. A scholar is included among the top collaborators of Ann Vanderplas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann Vanderplas. Ann Vanderplas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhou, Zheng, Alfred Rademaker, Leo I. Gordon, et al.. (2016). High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex. Journal of the National Comprehensive Cancer Network. 14(10). 1274–1281. 7 indexed citations
2.
3.
4.
Zhou, Zheng, Laurie H. Sehn, Alfred Rademaker, et al.. (2013). An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 123(6). 837–842. 609 indexed citations breakdown →
5.
Vanderplas, Ann, Allison Crosby‐Thompson, Gregory A. Abel, et al.. (2013). Transformed non‐Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. British Journal of Haematology. 163(4). 487–495. 49 indexed citations
6.
Lin, Nancy U., Ann Vanderplas, Melissa E. Hughes, et al.. (2012). Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network. Cancer. 118(22). 5463–5472. 475 indexed citations breakdown →
7.
LaCasce, Ann S., Jonathan L. Vandergrift, Maria Alma Rodriguez, et al.. (2012). Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 119(9). 2093–2099. 63 indexed citations
8.
Kumar, Anita, Ann Vanderplas, Ann S. LaCasce, et al.. (2011). Lack of benefit of central nervous system prophylaxis for diffuse large B‐cell lymphoma in the rituximab era. Cancer. 118(11). 2944–2951. 66 indexed citations
9.
Abel, Gregory A., Ann Vanderplas, Maria Alma Rodriguez, et al.. (2011). High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leukemia & lymphoma. 53(6). 1113–1116. 26 indexed citations
10.
11.
12.
13.
Lin, NU, Ann Vanderplas, Melissa E. Hughes, et al.. (2009). Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). Journal of Clinical Oncology. 27(15_suppl). 543–543. 29 indexed citations
14.
Stockl, Karen M., Ann Vanderplas, L Nicklasson, et al.. (2006). An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe. Current Medical Research and Opinion. 23(1). 133–146. 59 indexed citations
15.
Darkow, Theodore, et al.. (2005). Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. Current Medical Research and Opinion. 21(10). 1583–1594. 50 indexed citations
16.
Yu-Isenberg, Kristina, Ann Vanderplas, Eunice Chang, & Hemal Shah. (2005). Utilization and Medical Care Expenditures in Patients with Chronic Obstructive Pulmonary Disease. Disease Management & Health Outcomes. 13(6). 405–412. 4 indexed citations
17.
Stockl, Karen M., Ann Vanderplas, Eskinder Tafesse, & Eunice Chang. (2004). Costs of Lower-Extremity Ulcers Among Patients With Diabetes. Diabetes Care. 27(9). 2129–2134. 157 indexed citations
18.
White, TJ, Ann Vanderplas, Eunice Chang, Christopher M. Dezii, & Geoffrey D. Abrams. (2004). The Costs of Non-Adherence to Oral Antihyperglycemic Medication in Individuals with Diabetes Mellitus and Concomitant Diabetes Mellitus and Cardiovascular Disease in a Managed Care Environment. Disease Management & Health Outcomes. 12(3). 181–188. 19 indexed citations
19.
White, TJ, et al.. (2003). Economic Impact of Patient Adherence with Antidepressant Therapy Within a Managed Care Organization. Disease Management & Health Outcomes. 11(12). 817–822. 28 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aart Beeker Breakdown of academic impact, for papers by Pascal Wolter Breakdown of academic impact, for papers by Stephen J. Noga Breakdown of academic impact, for papers by Daniel T. Ruan Breakdown of academic impact, for papers by Antonella Brunello Breakdown of academic impact, for papers by Janine Nuver Breakdown of academic impact, for papers by Uma Kher Breakdown of academic impact, for papers by Jennifer Kim Breakdown of academic impact, for papers by Azeez Farooki Breakdown of academic impact, for papers by J Rovenský
Rankless by CCL
2026